Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 66 - 71 |
| Number of pages | 6 |
| Journal | Current Opinion in Nephrology and Hypertension |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2012 |
Cite this
}
The endothelin system and endothelin receptor antagonists. / Jandeleit-Dahm, Karin Agnes Maria; Watson, Anna.
In: Current Opinion in Nephrology and Hypertension, Vol. 21, No. 1, 2012, p. 66 - 71.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - The endothelin system and endothelin receptor antagonists
AU - Jandeleit-Dahm, Karin Agnes Maria
AU - Watson, Anna
PY - 2012
Y1 - 2012
N2 - There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.
AB - There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.
UR - http://www.ncbi.nlm.nih.gov/pubmed/22123210
U2 - 10.1097/MNH.0b013e32834dde48
DO - 10.1097/MNH.0b013e32834dde48
M3 - Article
VL - 21
SP - 66
EP - 71
JO - Current Opinion in Nephrology and Hypertension
JF - Current Opinion in Nephrology and Hypertension
SN - 1062-4821
IS - 1
ER -